| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
103.12(B) |
| Last
Volume: |
259,279 |
Avg
Vol: |
765,410 |
| 52
Week Range: |
$692.45 - $993.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
168,566 |
236,471 |
279,472 |
438,206 |
| Total Sell Value |
$164,437,486 |
$226,505,895 |
$262,153,799 |
$373,147,368 |
| Total People Sold |
8 |
14 |
16 |
18 |
| Total Sell Transactions |
15 |
42 |
60 |
120 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bassler Bonnie L |
Director |
– • – |
2024-01-03 |
4 |
OE |
$380.95 |
$314,665 |
D/D |
826 |
2,208 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2024-01-03 |
4 |
D |
$912.30 |
$22,344,964 |
D/D |
(24,493) |
39,543 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2024-01-03 |
4 |
OE |
$399.66 |
$13,588,440 |
D/D |
34,000 |
64,036 |
|
- |
|
| Schenkein David P |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
42 |
282 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
1,382 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2024-01-02 |
4 |
AS |
$900.00 |
$1,005,300 |
D/D |
(1,117) |
1,247 |
|
8% |
|
| Zoghbi Huda Y |
Director |
– • – |
2024-01-02 |
4 |
OE |
$391.92 |
$437,775 |
D/D |
1,117 |
2,364 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
6,382 |
|
- |
|
| Guarini Kathryn |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
42 |
282 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2024-01-02 |
4 |
D |
$888.34 |
$373,991 |
D/D |
(421) |
22,036 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2024-01-02 |
4 |
OE |
$378.98 |
$246,337 |
D/D |
650 |
22,457 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
1,382 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
1,382 |
|
- |
|
| Sing George L |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
26,349 |
|
- |
|
| Thompson Craig B. |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
454 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2024-01-02 |
4 |
AS |
$873.91 |
$239,451 |
D/D |
(274) |
15,062 |
|
8% |
|
| Yancopoulos George |
Bd. Co-Chair, President & CSO |
• • – |
2024-01-02 |
4 |
AS |
$900.00 |
$15,163,200 |
I/I |
(16,848) |
180,000 |
|
8% |
|
| Coles N Anthony |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
1,393 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
18,482 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2024-01-02 |
4 |
AS |
$873.91 |
$89,990 |
D/D |
(100) |
18,347 |
|
8% |
|
| Poon Christine A |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
2,172 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-28 |
4 |
D |
$884.88 |
$541,547 |
D/D |
(612) |
21,807 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-28 |
4 |
OE |
$378.98 |
$322,133 |
D/D |
850 |
22,419 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-27 |
4 |
D |
$872.21 |
$472,738 |
D/D |
(542) |
21,569 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-27 |
4 |
OE |
$378.98 |
$284,235 |
D/D |
750 |
22,111 |
|
- |
|
2414 Records found
|
|
Page 4 of 97 |
|
|
4.45 (0.45%) 
